We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Artificial Heart Tissue Developed in Vitro

By Biotechdaily staff writers
Posted on 20 Mar 2006
Trials of a method to engineer blood vessels within the tissue of previously engineered heart muscle have resulted in significant improvement in the heart function of rats, according to a new study.

Researchers at the University of Michigan (Ann Arbor, USA) and the department of biomedical engineering at the University of North Carolina (Chapel Hill, USA) were successful in producing blood vessels within heart muscle tissue. More...
Three-dimensional cardiac tissue, termed "cardioids,” was engineered in vitro from a monolayer of cardiac cells. The cardioids were then sutured onto a support framework and implanted in a subcutaneous pocket in recipient rats.

Three weeks after implantation, the cardioids were recovered for in vitro force testing and histologic evaluation. The results demonstrated the presence of viable cells within the explanted cardioids and the presence of vascularization. Electron micrographs revealed the presence of large amounts of aligned contractile proteins and a high degree of intercellular connectivity. The tissue-engineered construct remained viable even after the three-week implantation period, maintaining cardiac-specific function. The study was published in the November 2005 edition of the journal Artificial Organs.

"The long-term goal of cardiac tissue engineering is to generate functional cardiac muscle in vitro,” stated lead researcher, Ravi K. Birla. "Work in this area could lead to the formation of functional heart muscle that can someday help patients with acute heart failure.”



Related Links:
University of Michigan
University of North Carolina

Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
New
Automated Urinalysis Solution
UN-9000
New
Rapid Sepsis Test
SeptiCyte RAPID
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.